查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1769601

醫藥品中間體CDMO的全球市場:各用途，中間體類別，醫藥品類別，各地區 - 2035年前的預測分析

Global Pharmaceutical Intermediate CDMO Market Research Report by Application, by Type of Intermediate, by Drug Type, and by Region Forecast Analysis till 2035
出版日期: | 出版商: Market Research Future | 英文 146 Pages | 訂單完成後即時交付

價格

2024年，全球醫藥中間體CDMO市場規模為1,617.989億美元。預計2024年至2035年，該市場規模將達3,467.443億美元，複合年增長率為7.4%。

受多種因素影響，全球醫藥中間體CDMO市場正快速擴張。製藥公司為提高效率和減輕營運負擔，越來越多地採用外包模式。對仿製藥和生物相似藥的需求日益增長，尤其是在中低收入國家，是主要的成長因素。此外，中間體合成技術的進步和新藥製劑的複雜性，促使企業尋求專業的CDMO支援。新興國家醫療基礎設施的建設也促進了市場的發展。

另一方面，嚴格的監管合規要求和漫長的審批週期往往會阻礙進展。高昂的資本和營運成本、智慧財產權相關風險以及持續的供應鏈中斷都是顯著的障礙。缺乏先進的化學專業知識也是一個課題。儘管存在這些問題，但透過與生物技術公司建立策略合作夥伴關係，以及對客製化、患者專用藥物解決方案日益增長的需求，該市場仍然存在著廣闊的機會。

產業區隔

按應用領域，全球市場細分為腫瘤學、心血管疾病、中樞神經系統和神經系統疾病以及傳染病。

依藥物類型，全球醫藥中間體 CDMO 市場包括仿製藥和品牌藥。

全球醫藥中間體 CDMO 市場按中間體類型細分，包括活性藥物成分 (API)、生物中間體、輔料和添加劑以及核苷酸中間體。

依地區劃分，全球醫藥中間體CDMO市場分為北美、歐洲、南美、中東和非洲、亞太地區。

區域分析

北美醫藥中間體CDMO市場規模最大、發展最成熟，其中美國憑藉其高科技基礎設施、巨額研發投入以及FDA嚴格的品質監管而處於領先地位。加拿大生物製藥產業的成長進一步增強了該地區的實力。

歐洲既迎合國內巨頭，也迎合全球企業，注重法規合規性、複雜合成的創新以及符合循環經濟原則的可持續生產方法。

以中國和印度為首的亞太地區是成長最快的地區。經濟高效的製造、大規模的設施和一體化的供應鏈使具有競爭力的中間體生產成為可能。

拉丁美洲各國面臨不同的監管框架，但正在透過區域合作努力實現統一的標準。具有競爭力的勞動力成本和靠近美國的地理位置是其優勢，但基礎設施的限制在一定程度上阻礙了其成長。

在中東和非洲，CDMO主要透過生產仿製藥和基本藥物的中間體來服務當地和鄰近市場。該地區位於亞洲和歐洲之間，預計將成為醫藥物流和中間體供應的潛在樞紐。隨著全球供應鏈的發展，中東和非洲地區作為跨洲製造橋樑的角色可能會更加突出。

主要參與者

賽默飛世爾科技、Raghava Life Sciences Pvt LTD.、Cambrex Corporation、Actylis、Chiracon GmbH、Codexis, Inc.、Arkema S.A.、龍沙集團、康泰倫特和浙江九洲藥業股份有限公司是全球醫藥中間體CDMOMO市場的主要競爭對手。

本報告調查了全球醫藥中間體CDMO市場，並提供了市場概況、按應用、中間體類型、藥品類型和地區劃分的趨勢以及參與市場的公司概況。

目錄

第1章 摘要整理

第2章 市場簡介

第3章 調查手法

第4章 市場動態

  • 簡介
  • 促進因素
    • 藥廠外包業務不斷增加
    • 仿製藥和生物相似藥需求不斷成長
    • 中間體合成技術的進步
    • 藥物分子日益複雜
    • 向新興市場擴張
  • 阻礙因素
    • 嚴格的監管合規和複雜的審批流程
    • 高昂的營運和資本支出成本
    • 智慧財產權 (IP) 風險與保密問題
    • 供應鏈中斷與原料材料短缺
    • 先進技術與利基化學專業知識有限
  • 機遇
    • 與生技公司建立策略夥伴關係
    • 專注於個人化醫療解決方案
  • COVID的影響分析-

第5章 市場要素分析

  • 供應鏈分析
    • 原料採購
    • 調查，開發，流程最佳化
    • 製造和品管
    • 包裝，保管，物流，發送，對客戶的發送
  • 波特的五力分析

第6章 全球醫藥品中間體CDMO市場(中間體類別)

  • 簡介
  • 原料藥(API)
  • 賦形劑及添加物

第7章 全球醫藥品中間體CDMO市場(醫藥品類別)

  • 簡介
  • 學名藥
  • 品牌醫藥品

第8章 全球醫藥品中間體CDMO市場(各用途)

  • 簡介
  • 腫瘤學
  • 心血管疾病
  • 中樞神經系統及神經疾病
  • 感染疾病
  • 其他

第9章 全球醫藥品中間體CDMO市場(各地區)

  • 世界
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區
    • 中國
    • 韓國
    • 印度
    • 日本
    • 印尼
    • 馬來西亞
    • 泰國
    • 其他
  • 南美
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他
  • 中東·非洲
    • GCC各國
    • 南非
    • 其他

第10章 競爭情形

  • 簡介
  • 市場佔有率分析，2024年
  • 競爭儀表板

第11章 企業簡介

  • RAGHAVA LIFE SCIENCES PVT LTD
  • ACTYLIS
  • CHIRACON GMBH
  • CODEXIS, INC.
  • ARKEMA S.A.
  • LONZA GROUP AG
  • THERMO FISHER SCIENTIFIC(PATHEON)
  • CAMBREX CORPORATION
  • CATALENT, INC.
  • ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD

Global Pharmaceutical Intermediate CDMO Market Research Report by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast Analysis till 2035

Industry Overview

In 2024, global pharmaceutical intermediate CDMO market was valued at USD 161,798.9 million. It is projected to increase at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2035, reaching USD 346,744.3 million.

The global market for Pharmaceutical Intermediate CDMOs is expanding rapidly due to various contributing factors. Outsourcing by pharmaceutical firms is on the rise as they aim to enhance efficiency and reduce operational burdens. The increasing need for generic drugs and biosimilars, especially in low- and middle-income countries, is a major growth driver. Additionally, advancements in intermediate synthesis technologies and the complex nature of new drug formulations are pushing companies toward specialized CDMO support. The growth of healthcare infrastructure in emerging economies is also enhancing the market landscape.

On the flip side, stringent regulatory compliance requirements and lengthy approval timelines often hamper progress. High capital and operational expenses, intellectual property-related risks, and ongoing supply chain disruptions present notable barriers. A shortage of expertise in advanced chemistry remains another challenge. Despite these issues, the market holds promising opportunities through strategic alliances with biotechnology companies and the increasing demand for tailored, patient-specific medicine solutions.

Industry Segmentations

In terms of application types, the global market is divided into oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.

Based on the drug type, global pharmaceutical intermediate CDMO market comprises generic drugs, branded drug.

Global Pharmaceutical intermediate CDMO market has been categorized by type of intermediate, includes active pharmaceutical ingredients (APIS), biologics intermediates, excipients and additives, nucleotide intermediates.

Regionally, global pharmaceutical intermediate CDMO market divided into North America, Europe, South America, Middle East and Africa, and Asia Pacific.

Regional Analysis

The North American market for pharmaceutical intermediate CDMOs is the largest and most sophisticated, with the U.S. leading due to high-tech infrastructure, heavy R&D investments, and FDA-enforced quality regulations. Canada's rising biopharmaceutical industry further supports regional strength.

Europe caters to both domestic powerhouses and global players, emphasizing regulatory compliance, innovation in complex syntheses, and sustainable production practices aligned with circular economy principles.

Asia Pacific, spearheaded by China and India, is witnessing the fastest growth. Cost-effective manufacturing, large-scale facilities, and integrated supply chains enable competitive production of intermediates.

Latin America, while facing diverse regulatory frameworks across countries, is working toward unified standards through regional cooperation. Competitive labor costs and proximity to the U.S. are advantageous, though growth is somewhat hindered by infrastructure constraints.

In the Middle East and Africa, CDMOs largely serve local and neighboring markets by producing intermediates for generic medicines and essential drugs. The region's favorable location between Asia and Europe positions it as a potential hub in pharmaceutical logistics and intermediate supply. As global supply chains evolve, MEA's role may become more pronounced in bridging manufacturing efforts across continents.

Key Players

Thermo Fisher Scientific, Raghava Life Sciences Pvt LTD., Cambrex Corporation, Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the key competitors of the global pharmaceutical intermediate CDMO market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 MARKET OVERVIEW:
  • 1.2 MARKET SEGMENTATION
  • 1.3 COMPETITIVE LANDSCAPE
  • 1.4 FUTURE OUTLOOK

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 Data Mining Process
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 Secondary Research Data Flow:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 Primary Research DATA FLOW:
    • 3.5.2 Primary Research: Number of Interviews conducted
    • 3.5.3 Primary Research: Regional Coverage
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 Revenue Analysis Approach
    • 3.6.2 Data forecasting
    • 3.6.3 Data Forecasting Technique
  • 3.7 DATA MODELING
    • 3.7.1 microeconomic factor analysis:
    • 3.7.2 Data modeling:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 Increasing Outsourcing by Pharmaceutical Companies
    • 4.2.2 Rising Demand for Generic Drugs and Biosimilars
    • 4.2.3 Technological Advancements in Intermediate Synthesis
    • 4.2.4 Growing Complexity of Drug Molecules
    • 4.2.5 Expansion in Emerging Markets
  • 4.3 RESTRAINTS
    • 4.3.1 Stringent Regulatory Compliance and Complex Approval Processes
    • 4.3.2 High Operational and Capital Expenditure Costs
    • 4.3.3 Property (IP) Risks and Confidentiality Concerns
    • 4.3.4 Supply Chain Disruptions and Raw Material Shortages
    • 4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry
  • 4.4 OPPORTUNITY
    • 4.4.1 Strategic Partnerships with Biotech Firms
    • 4.4.2 Focus on Personalized Medicine Solutions
  • 4.5 IMPACT ANALYSIS OF COVID - 19

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 Raw Material Sourcing & Procurement
    • 5.1.2 Research, Development, & Process Optimization
    • 5.1.3 Manufacturing & Quality Control
    • 5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 Threat of New Entrants (Low to Moderate)
    • 5.2.2 Bargaining Power of Suppliers (Moderate)
    • 5.2.3 Threat of Substitutes (Low to Moderate)
    • 5.2.4 Bargaining Power of Buyers (High)
    • 5.2.5 Intensity of Rivalry (High)

6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE

  • 6.1 INTRODUCTION
  • 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
  • 6.3 EXCIPIENTS & ADDITIVES

7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE

  • 7.1 INTRODUCTION
  • 7.2 GENERIC DRUGS
  • 7.3 BRANDED DRUGS

8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
  • 8.3 CARDIOVASCULAR DISEASES
  • 8.4 CNS & NEUROLOGICAL DISORDERS
  • 8.5 INFECTIOUS DISEASES
  • 8.6 OTHERS

9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION

  • 9.1 GLOBAL
  • 9.2 NORTH AMERICA
    • 9.2.1 USA
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 united kingdom
    • 9.3.2 germany
    • 9.3.3 france
    • 9.3.4 italy
    • 9.3.5 spain
    • 9.3.6 RUSSIA
    • 9.3.7 rest of europe
  • 9.4 ASIA PACIFIC
    • 9.4.1 china
    • 9.4.2 South Korea
    • 9.4.3 indiA
    • 9.4.4 Japan
    • 9.4.5 indonesia
    • 9.4.6 malaysia
    • 9.4.7 thailand
    • 9.4.8 rest of asia pacific
  • 9.5 SOUTH AMERICA
    • 9.5.1 Mexico
    • 9.5.2 Brazil
    • 9.5.3 argentina
    • 9.5.4 rest of south america
  • 9.6 MIDDEL EAST AND AFRICA
    • 9.6.1 gcc countries
    • 9.6.2 south africa
    • 9.6.3 rest of middle east & africa

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS, 2024SS
  • 10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

  • 11.1 RAGHAVA LIFE SCIENCES PVT LTD
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 Key Development
    • 11.1.3 SWOT ANALYSIS
    • 11.1.4 Key Strategy
  • 11.2 ACTYLIS
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 PRODUCT OFFERED
    • 11.2.3 Key Development
    • 11.2.4 SWOT ANALYSIS
    • 11.2.5 Key Strategy
  • 11.3 CHIRACON GMBH
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 PRODUCT OFFERED
    • 11.3.3 SWOT ANALYSIS
    • 11.3.4 Key Strategy
  • 11.4 CODEXIS, INC.
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 PRODUCT OFFERED
    • 11.4.3 Key Development
    • 11.4.4 SWOT ANALYSIS
    • 11.4.5 financial analysis
    • 11.4.6 Key Strategy
  • 11.5 ARKEMA S.A.
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 PRODUCT OFFERED
    • 11.5.3 SWOT ANALYSIS
    • 11.5.4 financial analysis
    • 11.5.5 Key Strategy
  • 11.6 LONZA GROUP AG
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 PRODUCT OFFERED
    • 11.6.3 Key Development
    • 11.6.4 SWOT ANALYSIS
    • 11.6.5 financial analysis
    • 11.6.6 Key Strategy
  • 11.7 THERMO FISHER SCIENTIFIC (PATHEON)
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 PRODUCT OFFERED
    • 11.7.3 Key Development
    • 11.7.4 SWOT ANALYSIS
    • 11.7.5 financial analysis
    • 11.7.6 Key Strategy
  • 11.8 CAMBREX CORPORATION
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 PRODUCT OFFERED
    • 11.8.3 Key Development
    • 11.8.4 SWOT ANALYSIS
    • 11.8.5 Key Strategy
  • 11.9 CATALENT, INC.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 PRODUCT OFFERED
    • 11.9.3 Key Development
    • 11.9.4 SWOT ANALYSIS
    • 11.9.5 financial analysis
    • 11.9.6 Key Strategy
  • 11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 PRODUCT OFFERED
    • 11.10.3 Key Development
    • 11.10.4 SWOT ANALYSIS
    • 11.10.5 financial analysis
    • 11.10.6 Key Strategy

LIST OF TABLES

  • TABLE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 2 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 3 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 4 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 5 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 6 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 7 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 8 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 9 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 10 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 11 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 12 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 13 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 14 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 15 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 16 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 17 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 18 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 19 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 20 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 21 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 22 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 23 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 24 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 25 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 26 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 27 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 28 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 29 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 30 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 31 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 32 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 33 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 34 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 35 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 36 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 37 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 38 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 39 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 41 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 42 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 43 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 44 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 45 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 46 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 47 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 48 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 49 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 50 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 51 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 52 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 53 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 54 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 55 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 56 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 57 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 58 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 59 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 60 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 61 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 62 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 63 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 64 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 65 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 66 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 67 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 68 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 69 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 70 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 71 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 72 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 73 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 74 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 75 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 76 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 77 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 78 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 79 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 80 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 81 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 82 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 83 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 84 MIDDEL EAST AND AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 85 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 87 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 88 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 89 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 90 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 91 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 92 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 93 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 94 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 95 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 96 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 97 RAGHAVA LIFE SCIENCES PVT LTD: PRODUCT OFFERED
  • TABLE 98 ACTYLIS: PRODUCT OFFERED
  • TABLE 99 ACTYLIS: PRODUCT OFFERED
  • TABLE 100 CHIRACON GMBH: PRODUCT OFFERED
  • TABLE 101 CODEXIS, INC.: PRODUCT OFFERED
  • TABLE 102 CODEXIS, INC.: PRODUCT OFFERED
  • TABLE 103 ARKEMA S.A.: PRODUCT OFFERED
  • TABLE 104 LONZA GROUP AG: PRODUCT OFFERED
  • TABLE 105 LONZA GROUP AG: PRODUCT OFFERED
  • TABLE 106 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
  • TABLE 107 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
  • TABLE 108 CAMBREX CORPORATION: PRODUCT OFFERED
  • TABLE 109 CAMBREX CORPORATION: PRODUCT OFFERED
  • TABLE 110 CATALENT, INC.: PRODUCT OFFERED
  • TABLE 111 CATALENT, INC.: PRODUCT OFFERED
  • TABLE 112 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED
  • TABLE 113 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKETSEGMENT
  • FIGURE 2 DRIVER IMPACT ANALYSIS (2018-2035)
  • FIGURE 3 RESTRAINT IMPACT ANALYSIS (2018-2035)
  • FIGURE 4 SUPPLY CHAIN ANALYSIS
  • FIGURE 5 PORTER'S FIVE FORCES MODEL: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
  • FIGURE 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2024 (% SHARE)
  • FIGURE 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2024 (% SHARE)
  • FIGURE 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2024 (% SHARE)
  • FIGURE 10 NORTH AMERICAN MARKET: SWOT ANALYSIS
  • FIGURE 11 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 12 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 13 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 14 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 15 EUROPE MARKET: SWOT ANALYSIS
  • FIGURE 16 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 17 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 18 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 19 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
  • FIGURE 21 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 24 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 25 SOUTH AMERICA MARKET: SWOT ANALYSIS
  • FIGURE 26 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 27 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 28 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 29 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 30 MIDDEL EAST AND AFRICA: SWOT ANALYSIS
  • FIGURE 31 MIDDEL EAST AND AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 32 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 33 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 34 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 35 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 36 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET: COMPETITIVE ANALSIS, 2024
  • FIGURE 37 COMPETITOR DASHBOARD: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
  • FIGURE 38 RAGHAVA LIFE SCIENCES PVT LTD: SWOT ANALYSIS
  • FIGURE 39 ACTYLIS: SWOT ANALYSIS
  • FIGURE 40 CHIRACON GMBH: SWOT ANALYSIS
  • FIGURE 41 CODEXIS, INC.: SWOT ANALYSIS
  • FIGURE 42 ARKEMA S.A.: SWOT ANALYSIS
  • FIGURE 43 LONZA GROUP AG: SWOT ANALYSIS
  • FIGURE 44 THERMO FISHER SCIENTIFIC (PATHEON): SWOT ANALYSIS
  • FIGURE 45 CAMBREX CORPORATION: SWOT ANALYSIS
  • FIGURE 46 CATALENT, INC: SWOT ANALYSIS
  • FIGURE 47 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: SWOT ANALYSIS